Bristol-Myers Squibb Q4 Adjusted EPS $1.70 Beats $1.53 Estimate, Sales $11.48B Beat $11.19B Estimate
Portfolio Pulse from Benzinga Newsdesk
Bristol-Myers Squibb (BMY) reported Q4 adjusted EPS of $1.70, surpassing the $1.53 estimate, and sales of $11.48B, exceeding the $11.19B estimate. This represents a 6.59% decrease in EPS and a 0.62% increase in sales from the same period last year.
February 02, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol-Myers Squibb reported a Q4 adjusted EPS of $1.70, beating estimates, and sales of $11.48B, also above expectations.
Beating both EPS and sales estimates typically leads to positive investor sentiment and can result in a short-term stock price increase. The reported decrease in EPS year-over-year might temper the positive impact slightly, but the overall beat on expectations is likely to be the dominant factor in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100